

REVISED MI DEFINITIONS IMPLICATIONS FOR CLINICAL TRIALS

Maarten L Simoons Thoraxcenter - Erasmus MC Rotterdam - The Netherlands

TRITON Prasugrel ACS + PCI

n = 13,608 moderate / high risk ACS, all PCI



Wiviott NEJM 2007







MI IN TRIALS: CEC - INVESTIGATOR



MI IN TRIALS: CEC - INVESTIGATOR

- Outcome of trial may vary, depending on definitions of primary endpoints, particularly MI
- The definition should be pre-specified, according to ESC, ACC, AHA, WHF guidelines
- Similarly pre-specify definitions of bleeding, stroke etc.
- Both CEC and investigator reported endoints should be reviewed by regulatory agencies: EMA, FDA

- ESC, ACC, AHA Eur Heart J 2000 - MI = necrosis caused by ischaemia
- ESC, ACC, AHA, WHF Eur Heart J 2007 - distinguish different causes (types) of MI
- ESC, ACC, AHA, WHF Eur Heart J 2012
- more sensitive markers of myocardial necrosis
- myocardial necrosis in critically ill (MI or injury)
- myocardial necrosis with PCI or CABG



- ESC, ACC, AHA Eur Heart J 2000 - MI = necrosis caused by ischaemia
- ESC, ACC, AHA, WHF Eur Heart J 2007 - distinguish different causes (types) of MI
- ESC, ACC, AHA, WHF Eur Heart J 2012
- more sensitive markers of myocardial necrosis
- myocardial necrosis in critically ill (MI or injury)
- myocardial necrosis with PCI or CABG



Evidence of myocardial necrosis

 Rise and/or fall of markers of necrosis (troponin) with at least one value > 99% URL

In clinical setting of myocardial ischaemia

- Symptoms
- New (presumed new) ST-T changes or LBBB
- Development of (new) Q waves
- Imaging evidence of loss of viable myocardium or new wall motion abnormality
- Intracoronary thrombus by angio / autopsy

Erasmus MC

- ESC, ACC, AHA Eur Heart J 2000 - MI = necrosis caused by ischaemia
- ESC, ACC, AHA, WHF Eur Heart J 2007 - distinguish different causes (types) of MI
- ESC, ACC, AHA, WHF Eur Heart J 2012
- more sensitive markers of myocardial necrosis
- myocardial necrosis in critically ill (MI or injury)
- myocardial necrosis with PCI or CABG

MYOCARDIAL NECROSIS

Primary myocardial ischaemia (MI type 1)

- Plaque rupture / fissure
- Intracoronary thrombus

Ischaemia by supply / demand imbalance

- Tachy-brady-arrhythmia
- Aortic dissection, severe Aortic valve disease
- Hypertrophic cardiomyopathy
- Cardiogenic, hypovolemic, septic shock
- Severe anaemia
- Hypertension (+/- LVH)
- Coronary spasm, embolism, vasculitis
- Endothelial dysfunction without significant CAD

MYOCARDIAL NECROSIS

Injury not related to myocardial ischaemia

- Cardiac contusion, surgery, ablation, pacing, defibrillator shock
- Rhabdomyolysis (cardiac involvement)
- Myocarditis
- Cardiotoxic agents (antracyclines, herceptin)

Multifactorial / undetermined myocardial injury

- Heart failure, Stress (Takotsubo) cardiomyopathy
- Pulmonary embolism, pulmonary hypertension
- Sepsis and critical ill patients
- Renal failure, stroke, intracranial bleeding
- Amyloidosis, sarcoidosis, strenuous exercise

- ESC, ACC, AHA Eur Heart J 2000 - MI = necrosis caused by ischaemia
- ESC, ACC, AHA, WHF Eur Heart J 2007 - distinguish different causes (types) of MI
- ESC, ACC, AHA, WHF Eur Heart J 2012
- more sensitive markers of myocardial necrosis
- myocardial necrosis in critically ill (MI or injury)
- myocardial necrosis with PCI or CABG



PCI RELATED MI

- Continuing discussion about relevance of PCI related myocardial injury:
 - It is often unavoidable,
 - however it is better if such injury could be limited It can be limited by careful catheter / wire
 - handling and by anti-thrombotic therapy
 - Even in patients with successful, elective PCI and a normal troponin level before the procedure, troponin elevation (myocardial injury) is frequent The long-term consequences are uncertain
- Similarly, in cardiac surgery some injury is often unavoidable

PCI RELATED MI



Mortality at 6 months follow-up (%) Akkerhuis, Simoons Circulation 2002

PCI related

Spontaneous



SPONTANEOUS / PCI RELATED MI

Adjusted Risk of CV Death by MI Classification



SPONTANEOUS / PCI RELATED MI

Long-term cardiovascular mortality after spontaneous or procedure-related MI

MI	Study	Hazard ratio for CV death (95% CI)	HR (95% CI)	
Spontaneous	FRISC II ICTUS RITA-3		4.37 (2.87 - 6.67) 4.29 (2.13 - 8.64) 5.66 (3.42 - 9.38)	
	Total		4.52 (3.37 - 6.06)	
Procedure- related	FRISC II ICTUS ⊢ RITA-3		0.99 (0.44 - 2.23) 0.38 (0.12 - 1.22) 1.21 (0.30 - 4.87)	
	Total		0.66 (0.36 - 1.20)	
	°.	~ · · · · · · · · · · · · · · · · · · ·		

5467 patients, 212 PCI related MI, 236 spontaneous MI after enrollment, 5 year follow-up. FRISC II, ICTUS, RITA-3 Damman et al Circulation 2012

SPONTANEOUS / PCI RELATED MI

Discussion about relevance of PCI related injury:

- Elective PCI / ACS; varying follow-up
- Inclusion or exclusion of patients with elevated markers of necrosis before PCI
- Even if CK or CK-MB was normal before PCI, troponin might have been elevated
- Results may depend on method of analysis, some studies were underpowered

Consequences of PCI related myocardial injury are less severe than spontaneous MI, which is important for interpretation of trial results and for information to patients. Damman, Wallentin, Fox, Circ 2012

PCI RELATED MI

In patients with normal baseline (< 99th %) troponin elevation > 5 x 99th % within 48 hours after the procedure (arbitrary) are indicative of MI, if Evidence of prolonged ischemia (pain > 20 min) Ischemic ST changes (>20 min) or new Q waves Angiographic evidence of flow limiting complications: side branch occlusion, no-reflow, persistent low flow, embolization Imaging evidence of new loss of viable myocardium or new wall motion abnormality

ESC, ACC, AHA, WHF 2012

CABG RELATED MI

In patients with normal baseline (< 99th %) troponin elevation > 10 x 99th % within 48 hours after the procedure (arbitrary) are indicative of MI, if

- New Q waves or LBBB
- Angiographic evidence of graft- or coronary artery occlusion
 - Imaging evidence of new loss of viable myocardium or new wall motion abnormality

ESC, ACC, AHA, WHF 2012

REPORTING MI IN CLINICAL TRIALS

Troponin > 99 th %		1 - 3	3 - 5	5 - 10	> 10	Total
Spontaneous	1					
Secondary	2					
Death	3					
PCI related	4					
Stent occl. Restenosis						
CABG	5					

REPORTING MI IN CLINICAL TRIALS

Collect blood samples at *baseline and 3 – 6 hours* later in patients with possible / suspected MI (ACS). Collect samples before and 3 – 6 hrs after PCI / CABG

Assess cardiac *Troponin I / T*

(If Troponin cannot be measured use *CK-MB mass*) Interpret using 99th percentile URL for each laboratory

Present the definition of MI to be used in the trial analysis plan and define role of Clinical Event Cie

Report MI, and other endpoints. (trial definitions). Also report the full data table (Guidelines) such that alternative definitions can be applied in meta-analyses

REPORTING MI IN CLINICAL TRIALS

Troponin > 99 th %		1 - 3	3 - 5	5 - 10	> 10	Total
Spontaneous	1					
Secondary	2					
Death	3					
PCI related	4					
Stent occl. Restenosis						
CABG	5					

